Does UnitedHealthcare Cover Wegovy? 2026 Plan Guide

UnitedHealthcare is America's largest insurer, which means there is no single UnitedHealthcare answer, only plan-by-plan answers. Still, clear patterns hold across the company's books of business in 2026.

Many UnitedHealthcare plans cover Wegovy in 2026, but coverage depends on whether your employer purchased the weight-management drug benefit. Where covered, UHC and its pharmacy benefit manager Optum Rx require prior authorization with a BMI of 30 or higher, or 27 or higher with a weight-related condition, and most plans apply step therapy or a lifestyle-program requirement. Wegovy's added FDA approval for reducing cardiovascular risk gives heart patients a second coverage route that bypasses some weight-loss exclusions.

This guide breaks coverage down by plan type, walks the prior authorization criteria, and covers what to do when your specific plan opted out.

UnitedHealthcare Wegovy Coverage by Plan Type

Employer-sponsored plans are where most members live, and they split into two camps. Fully insured plans follow UHC's standard formularies, which list Wegovy as a covered weight-management GLP-1 with prior authorization on plans that include the anti-obesity benefit. Self-funded employer plans choose their own benefits, and a meaningful share exclude weight-loss drugs entirely; over half of patients seeking GLP-1 coverage nationally now face full formulary exclusions per industry tracking through 2026.

Individual marketplace (ACA) plans from UHC rarely cover weight-loss medications. UnitedHealthcare Medicare Advantage plans follow Medicare law, which excludes weight-loss coverage until the Medicare GLP-1 Bridge pilot starts July 1, 2026; Wegovy's cardiovascular indication already provides limited Part D coverage for members with established heart disease. UHC Community Plan (Medicaid) coverage follows your state's rules, with about 13 states covering GLP-1s for obesity.

The fastest way to know your situation: call the number on your card and ask two questions. Is Wegovy on my formulary, and does my plan include the weight-management drug benefit?

Optum Rx Prior Authorization Criteria for Wegovy

Where the benefit exists, Optum Rx applies consistent criteria. Adults need a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea. Plans commonly require documented participation in a reduced-calorie diet and exercise program, often for 3 to 6 months, plus a baseline weight on file.

Renewals add a results test. Continuation approvals typically require losing at least 5 percent of baseline body weight during the initial authorization period. Build weigh-ins into your medical record from day one, because missing weight documentation is the most common reason renewal requests fail.

The Cardiovascular Pathway Most Members Miss

In March 2024 the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight. That indication treats a disease, not weight, which matters on plans that exclude weight-loss drugs.

If you have established cardiovascular disease (a prior heart attack, stroke, or peripheral arterial disease) and a BMI of 27 or higher, your doctor can submit Wegovy under the cardiovascular indication. Some UHC plan documents that exclude anti-obesity medications still allow coverage under this label, and it is the standard route on Medicare Advantage plans today.

What Wegovy Costs on UnitedHealthcare

With an approved authorization, commercial copays commonly run $25 to $150 monthly depending on tier, and Novo Nordisk's savings card brings eligible commercial patients to as little as $0 to $25. High-deductible plan members pay the negotiated rate (typically $650 to $900) until the deductible is met.

Without coverage, NovoCare Pharmacy and major retail partners sell Wegovy for about $499 per month, and the federal TrumpRx channel lists semaglutide near $350 as it rolls out through 2026. List price remains roughly $1,350.